Coenzyme Q10 Role in Prevention of Contrast Induced Nephropathy in Acute Coronary Syndrome Patients.

Phase 4

Recruiting

• Conditions: Contrast-induced Nephropathy
• Interventions: Drug: Placebo; Drug: Coenzyme Q10 100 Milligrams Oral Capsule

• Registration Number: NCT06429345
• Lead Sponsor: Ain Shams University

Brief Summary

In this study the investigators aim to study the effect of supplementation of CoQ10 in decreasing the incidence of contrast induced acute kidney injury in patients with acute coronary syndrome undergoing coronary angiography.

Detailed Description

Patients who fulfilled the inclusion criteria and agreed to participate in the study will be randomly divided into 2 groups using their computer generated random numbers that group a will receive the coenzyme Q10 in addition to the standard preventive measures and group b will receive only the standard preventive measures without the coenzyme Q10.

Study Timeline

• Status Verified: 2024-03
• Study First Submitted: 2024-03-19
• Study First Submitted QC: 2024-05-23
• Study First Posted: 2024-05-28
• Study Start: 2024-06-15
• Last Update Submitted: 2024-06-27
• Last Update Posted: 2024-06-28
• Primary Completion: 2024-10-01
• Study Completion: 2024-11-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 250

Inclusion Criteria

• Patients who are 18 years or older.
• ST-elevation myocardial infarction (STEMI).
• Non ST-elevation myocardial infarction( NSTEMI).
• Unstable Angina (UA)

Exclusion Criteria

• Renal transplant patients.
• Preoperative bleeding .
• Intraoperative bleeding or hypotension.
• Patients taking any nephrotoxic medications

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo group	Placebo	Placebo Group received only the standard preventive measures
Coenzyme Q10 100 Milligrams Oral Capsule	Coenzyme Q10 100 Milligrams Oral Capsule	Coenzyme Group received coenzyme Q10 in addition to the the standard preventive measures

Primary Outcome Measures

Name	Time	Method
Percentage of the Creatinine rise in 1st 48-72 hours in ccu	48-72 hours	a rise in serum creatinine of at least 0.5 mg/dL or a 25% increase from baseline within 48 to 72 hours after contrast exposure

Trial Locations

Locations (2)

Ain Shams university hospitals; 🇪🇬 Cairo, Egypt

Ramy Mohamed Mostafa; 🇪🇬 Cairo, Egypt